Lilly cancer drug hits hurdle, panel recommends study continue

(Reuters) – An independent panel’s interim analysis of Eli Lilly and Co’s breast cancer drug abemaciclib showed the treatment did not meet the effectiveness criteria in a late-stage trial. If approved, abemaciclib is expected to compete with Pfizer Inc’s breast cancer drug, Ibrance, which brought in over half a billion dollars in second-quarter sales. The trial is designed to evaluate the safety and efficacy of abemaciclib, in combination with anti-estrogen drug fulvestrant, in patients with a form of advanced breast cancer.
Go to Source

Future of drug pricing: paying for benefits not per pill

A customer waits at the counter of a CVS Pharmacy store in PasadenaBy Ben Hirschler LONDON (Reuters) – Global pressure on health spending is forcing the $1 trillion-a-year pharmaceutical industry to look for new ways to price its products: charging based on how much they improve patients&; health, rather than how many pills or vials are sold. In the United States, both parties are promising fresh action on drug prices whoever wins the White House. In Europe, economies are stalled, squeezing state health budgets.

Go to Source

1 46 47 48 49 50 125